Scholars Central

Conference abstractPublished 19 Apr 2022

Severe acute respiratory syndrome Coronavirus 2 antibodies among healthcare workers after a third dose of Vaccine in an intensive care unit

Authors: Claudia Lemos, Sofia Ferreira, Filipa Corte-Real, Catarina Lume, Susana Chaves, Jose Julio, Nobrega, Claudio Gouveia, Mariana Rodrigues, Cheila Placido, Dra M Isabel, Mendonca, Jose Alves, Graca Andrade

Intensive Care Department, Hospital Central do Funchal, Funchal, Portugal; Pathology, Hospital Central do Funchal, Funchal, Portugal

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The Coronavirus disease 2019 (COVID-19) and Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged in China in December 2019 as a public health crisis. Healthcare workers (HCWs) are a very important high-risk group of infection and the knowledge of SARS-CoV-2 antibody seroprevalence among this class is very important, not only to evaluate the success of public health interventions but also to comprehend the spread of COVID-19 among health institutions. The objective of this prospective study was to determine the seroprevalence of COVID-19 immunoglobulin G (IgG) antibodies after the third dose of vaccine administration and assess the symptomatology associated with the number of IgG antibodies. A total of 65 HCWs from an intensive care unit were studied at one month after the third administration of the COVID-19 vaccine. They were divided into two groups: IgG antibodies greater than 15.000 (group one) and less than 15.000 (group two). There was a seroprevalence of 78.5% (group 1) and 21.5% (group 2). Group 1 consisted mainly of male individuals (68.6%), unlike group 2 which consisted mainly of female individuals (92.9%). This was statistically significant (p<0.001). We also concluded that most of group 1 had more symptoms (94.1%) and a minority of group 2 had less symptoms (14.3%), being statistically significant (p<0.001). After the administration of the vaccine, group 1 had more symptoms (p<0.001). These symptoms were myalgias (50.8%), fever (27.7%), adenopathies (35.4%), asthenia (24.6%), vomiting (12.3%), diarrhea (10.8%), chills (6.2%), epigastric pain and arthralgia (1.5%). Our study concluded that male professionals with a higher number of IgG antibodies developed the most symptoms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical and Cellular Immunology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Claudia Lemos”
  • BylineArticles whose byline prints “Sofia Ferreira”
  • BylineArticles whose byline prints “Filipa Corte-Real”
  • BylineArticles whose byline prints “Catarina Lume”
  • BylineArticles whose byline prints “Susana Chaves”
  • BylineArticles whose byline prints “Jose Julio”
  • BylineArticles whose byline prints “Nobrega”
  • BylineArticles whose byline prints “Claudio Gouveia”